TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7978695
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (both doses)
Study: 2691812
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil and exercise (FE), N = 7, 50 ml of oil daily and 3 d.wk‐1 of aerobic exercise
Study: 2691812
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (F), N = 7, 50 ml of oil daily
Study: 2691812
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (CN), N = 10, 50 ml of oil daily
Study: 29948869
Drug: Acetaminophen iv
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen iv (n = 63)
Study: 21676083
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol tablets (25 µg, 4-hourly, max 5 doses)
Study: 21676083
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone (PGE2) gel (0.5 mg, 6-hourly, max 2 doses)
Study: 18458358
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) loading (5 g dicreatine citrate plus 10 g of flavored fructose powder per packet, 20 g/d for 5 days)
Study: 18458358
Drug: Placebo (Pl;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Pl; 10 g of flavored fructose powder per packet)
Study: 3512226
Drug: Nonretard isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonretard isosorbide dinitrate, 20 and 40 mg six times daily
Study: 31746542
Drug: 1% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tetracaine hydrochloride injection pure solution aerosol inhalation combined with oral 5 mL of dyclonine hydrochloride mucilage
Study: 31746542
Drug: Diluted tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted tetracaine hydrochloride injection (3 mL of 1% tetracaine hydrochloride injection + 3 mL of sterile water for injection) aerosol inhalation combined with oral 5 mL of dyclonine hydrochloride mucilage
Study: 19726771
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum (0.58 mg per injection)
Study: 18162014
Drug: Divalproex monotherapy
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex monotherapy (target dose level, 70‐90 ng/dL)
Study: 14609035
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg bid for 4 weeks
Study: 8851312
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol hydrobromide (600 micrograms) during 3-minute UNDW inhalation
Study: 8851312
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol hydrobromide (400 micrograms) during 1-minute UNDW inhalation
Study: 8851312
Drug: Inhaled oxitropium
Normalized name: oxitropium
DrugBank: Oxitropium (DB12086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxitropium bromide (300 micrograms) during 3-minute UNDW inhalation
Study: 6418654
Drug: Balanced AA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced AA solution with 10% branched chain amino acids (BCAA)
Study: 6418654
Drug: AA solution
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA solution with 60% BCAA
Study: 6418654
Drug: AA solution
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA solution with 67% alanine
Study: 2412070
Drug: Ketanserin (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (selective S2-serotonergic receptor antagonist)
Study: 2412070
Drug: Antiplatelet therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapies
Study: 24527467
Drug: 2 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 µg dexmedetomidine added to 3 mL (15 mg) hyperbaric bupivacaine
Study: 24527467
Drug: 4 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 µg dexmedetomidine added to 3 mL (15 mg) hyperbaric bupivacaine
Study: 24527467
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL saline added to 3 mL (15 mg) hyperbaric bupivacaine
Study: 21937481
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (LAmB) plus deferasirox (20 mg/kg/day for 14 days)
Study: 20826626
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dihydrocapsiate/d
Study: 20826626
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg dihydrocapsiate/d
Study: 20826626
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg dihydrocapsiate/d)
Study: 18379965
Drug: Multimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality therapy (including TUR, radiation, and chemotherapy)
Study: 18379965
Drug: Organ-preserving approach
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-preserving approach (including TUR and intravesical therapy)
Study: 10947687
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection peribulbar block
Study: 1428467
Drug: Active agents
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active agents
Study: 6230034
Drug: Ipratropium (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg)
Study: 31205487
Drug: SPMC oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPMC oral solution
Study: 25178112
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled fluticasone propionate (FP)
Study: 25178112
Drug: Standard-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose inhaled fluticasone propionate (FP)
Study: 22491567
Drug: Chlorhexidine‐gluconate (CHG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine‐gluconate (CHG) (4%) spray
Study: 22491567
Drug: Povidone‐iodine (PI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone‐iodine (PI) (10%) spray
Study: 16326674
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% plus lornoxicam 8 mg (Group RL)
Study: 1806490
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone (hGH) 0.03 mg/kg subcutaneously 3 times a week for 12 months (6-18 months experimental period)
Study: 1806490
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone (hGH)
Study: 6613689
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ascorbic acid daily for two weeks
Study: 6613689
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ascorbic acid daily
Study: 31805862
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Rifampicin (SDR) at double the regular dose (20 mg/kg) provided to eligible contacts aged two years and above in arms 2, 3, and 4.
Study: 28592299
Drug: Real biofield
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real biofield therapy
Study: 26466314
Drug: Dietary n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary n-3 polyunsaturated fatty acids (PUFAs) intake, mean intake 2.0 ± 1.3 g/day
Study: 26466314
Drug: Dietary alpha-linolenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary alpha-linolenic acid (ALA) intake, mean intake 1.5 ± 1.0 g/day
Study: 26466314
Drug: Ratio of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratio of n-6/n-3 PUFAs, mean ratio 9.5 ± 6.7 g/day
Study: 23549520
Drug: Prednisone and
Normalized name: chloroprednisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and valacyclovir plus physical therapy (n = 39)
Study: 23549520
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy only (n = 48)
Study: 21165628
Drug: L-arabinose (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arabinose (2 g) with sucrose (40 g)
Study: 21165628
Drug: Sucrose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (40 g) without L-arabinose
Study: 9413958
Drug: Oral 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 13-cis-retinoic acid at 20 mg/day
Study: 9413958
Drug: Oral 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 13-cis-retinoic acid at 40 mg every other day
Study: 8386921
Drug: Diltiazem (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (calcium antagonist)
Study: 8386921
Drug: Furosemide and
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide and Atenolol (loop diuretic and beta-blocker)
Study: 8386921
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and Diltiazem
Study: 3318429
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg nabumetone once daily
Study: 2429335
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen twice daily
Study: 3318429
Drug: Nabumetone (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (open-label treatment)
Study: 28426624
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg daily for 1 week, then up to 50 mg daily for 8 weeks)
Study: 23524365
Drug: Passive control
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive control (contralateral shoulder without treatment)
Study: 21383004
Drug: Night-time ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time ingestion of antihypertensives
Study: 21383004
Drug: Morning ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning ingestion of antihypertensives
Study: 19109560
Drug: Low-dose platelet
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose platelet transfusions (150-<300 x 10(9) platelets/product)
Study: 19109560
Drug: Standard-dose platelet
Normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose platelet transfusions (300-600 x 10(9) platelets/product)
Study: 19109560
Drug: Low-dose platelet
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose platelet transfusions
Study: 19109560
Drug: Standard-dose platelet
Normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose platelet transfusions
Study: 15187171
Drug: Bayley Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayley Infant Neurodevelopmental Screener (BINS) administered at 6 and 13 months
Study: 15187171
Drug: Bayley Scales
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayley Scales of Infant Development, second edition (BSID‐II) administered at 24 months
Study: 10211048
Drug: HF and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF and red-pepper (10 g) meal
Study: 28390503
Drug: Interactive media‐based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive media‐based, computer‐delivered depression treatment program (imbPST)
Study: 22336748
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment Control (NTC)
Study: 26297323
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (automated texting smoking intervention)
Study: 26678710
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1g every 4 hours for 72 hours)
Study: 24633277
Drug: 24-hour antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour antibiotic regimen (Ampicillin/Cloxacillin and Metronidazole)
Study: 24633277
Drug: 7-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day antibiotic regimen (Ampicillin/Cloxacillin and Metronidazole)
Study: 24633277
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of antibiotics for short term prophylaxis
Study: 24633277
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of antibiotics for long term prophylaxis
Study: 21920501
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy for pathological gambling plus a standard drug therapy for schizophrenia
Study: 21920501
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug therapy for schizophrenia
Study: 18333946
Drug: pH-balanced gel
Normalized name: acetic acid / oxyquinoline Vaginal Gel [Fem pH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-balanced gel (pH 3.8-4.2) with regular size, non-applicator tampons
Study: 18333946
Drug: Existing lubricating
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing lubricating gel (pH 5.1) with regular size, non-applicator tampons
Study: 24692816
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg/d)
Study: 15860521
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg once daily
Study: 9528197
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg thrice daily for 14 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Study: 9528197
Drug: Amoxycillin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (twice daily for 14 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Study: 9528197
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once daily for 6 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Study: 7930131
Drug: Oral Temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Temperature (OT)
Study: 7930131
Drug: Rectal Temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Temperature (RT)
Study: 3219156
Drug: KW-3049 (benidipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3049 (benidipine hydrochloride) 2 x 8 mg
Study: 3219156
Drug: Nifedipine 2
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 2 x 10 mg
Study: 29325517
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile (15 minutes of running or walking integrated into the school day for 12 months)
Study: 29325517
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile
Study: 30280946
Drug: CE 0.45
Normalized name: Femtrace 0.45mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.45 mg/MPA 1.5 mg
Study: 22325086
Drug: Valsartan add-on
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan add-on treatment
Study: 21436597
Drug: Non-ARB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ARB treatment (Control)
Study: 19159566
Drug: Drug-resistant regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant regimen (3RFT AM Ofx Pto PAS-INH/5RFT Ofx Pto PAS-INH)
Study: 19159566
Drug: MDR-TB patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDR-TB patients on drug-resistant regimen
Study: 19159566
Drug: Drug-resistant regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant regimen
Study: 8837903
Drug: Moclobemide 400
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 400 mg daily
Study: 7908356
Drug: Immediate zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate zidovudine (250 mg four times daily)
Study: 3067330
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (De‐Nol) 300 mg four times daily with ASA
Study: 3067330
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 2.5 g plus placebo
Study: 29288911
Drug: Perampanel monotherapy
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel monotherapy
Study: 29404725
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg + MTX
Study: 29404725
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg
Study: 29483080
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg
Study: 29404725
Drug: Tocilizumab 4
Normalized name: tocilizumab 400 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 4 mg + MTX
Study: 29404725
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg + MTX
Study: 29404725
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg + MTX
Study: 29483080
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg
Study: 29404725
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg + MTX, Sirukumab 100 mg + MTX, Sarilumab 200 mg + MTX
Study: 28490337
Drug: Conventional antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antidiabetic treatment
Study: 28490337
Drug: Sitagliptin and
Normalized name: sitagliptin and simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin and Conventional treatment
Study: 20214441
Drug: Amoxicillin-metronidazole combination
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-metronidazole combination and scaling and root planing
Study: 16388496
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of injections or STIs
Study: 14647223
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g recombinant human lactoferrin
Study: 9051165
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) at Zusanli (St. 36), Sanyinjiao (Sp. 6), Hegu (L.I.4), and Neiguan (P.6) points
Study: 9051165
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (1 mg)
Study: 31267698
Drug: ELISA-positive participants
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA-positive participants (GADA ≥ 5 U/mL)
Study: 31267698
Drug: ELISA-negative participants
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA-negative participants (GADA < 5 U/mL)
Study: 17336171
Drug: Antenatal screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal screening and treatment of mothers with penicillin
Study: 17336171
Drug: Point-of-care decentralized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care decentralized screening and treatment
Study: 10205213
Drug: 0.2% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% GTN three times daily
Study: 10205213
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose GTN starting at 0.2% with weekly 0.1% increments to a maximum of 0.6%
Study: 31663855
Drug: Blended CBT
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended CBT (10 weekly face-to-face sessions and 9 web-based sessions)
Study: 31663855
Drug: Standard CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CBT (15 to 20 weekly face-to-face sessions)
Study: 28556432
Drug: One-piece dental
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece dental implants (S1)
Study: 28556432
Drug: Two-piece dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-piece dental implants (S2)
Study: 21411512
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant methionyl human leptin (30 mg/day)
Study: 21411512
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant methionyl human leptin (80 mg/day)
Study: 18923838
Drug: Rheopheresis (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheopheresis (two treatments, each lasting about 2 hours, within 3 days)